ERBB4

Receptor tyrosine-protein kinase erbB-4

68,085 patent compounds predicted against ERBB4, 55,374 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL238877	1.00	16/20
SCHEMBL8223	0.40	13/20
SCHEMBL25309	0.82	11/20
SCHEMBL27049	0.79	11/20
SCHEMBL25689	0.76	11/20
SCHEMBL26377	0.76	11/20
SCHEMBL251657	0.61	11/20
SCHEMBL254281	0.61	11/20
SCHEMBL252515	0.58	11/20
SCHEMBL252516	0.58	11/20
SCHEMBL25359	1.00	10/20
SCHEMBL33158	1.00	10/20
SCHEMBL25412	0.89	10/20
SCHEMBL26310	0.89	10/20
SCHEMBL26269	0.88	10/20
SCHEMBL26756	0.83	10/20
SCHEMBL255881	0.78	10/20
SCHEMBL185491	0.56	10/20
SCHEMBL232373	0.56	10/20
SCHEMBL232374	0.56	10/20

Germline variants in ERBB4 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full ERBB4 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to ERBB4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)	PHASE3	COMPLETED
Overcoming Endocrine Resistance in Metastatic Breast Cancer	PHASE3	UNKNOWN
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive	PHASE3	COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）	PHASE2	RECRUITING
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules	PHASE2	UNKNOWN
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer	PHASE2	RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer	PHASE2	UNKNOWN
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer	PHASE2	COMPLETED
Afatinib in NSCLC With HER2 Mutation	PHASE2	COMPLETED
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance	PHASE2	COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)	PHASE1/PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Study of XL647 in Subjects With Non-Small-Cell Lung Cancer	PHASE2	COMPLETED
Letrozole, Herceptin in Her2neu +, Estrogen Receptor [ER] and/or Progesterone Receptor [PR] Positive, MBC	PHASE2	COMPLETED
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene	PHASE2	UNKNOWN
Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer	PHASE1	UNKNOWN
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma	PHASE1	COMPLETED
Assessing the Immunogenicity of pING-hHER3FL	PHASE1	ACTIVE_NOT_RECRUITING
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients	PHASE1	COMPLETED
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers	PHASE1	COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients	nan	UNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Squamous Cell Head and Neck Cancer (HNSCC) to Study Resistance Mechanisms Induced by Standard Therapy	nan	NOT_YET_RECRUITING
Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer	nan	RECRUITING
Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis	nan	UNKNOWN
K-RAS Oncogene Mutation in Patients With Advanced Non-Small Cell Lung Cancer Associated With Exposure to Wood Smoke and Tobacco Smoking: Therapeutic Implications	nan	COMPLETED
Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ERBB4 binder may also engage these)

Protein	Name	Similarity
Q62956	—	1.000	Q62956 →
Q61527	—	1.000	Q61527 →
Q9JIB4	—	0.945	Q9JIB4 →
Q6UXG2	—	0.942	Q6UXG2 →
A0JN27	—	0.940	A0JN27 →
Q13888	—	0.937	Q13888 →
Q5SP67	—	0.937	Q5SP67 →
Q6P1K8	—	0.936	Q6P1K8 →
Q2TBV5	—	0.936	Q2TBV5 →
Q96LI5	—	0.935	Q96LI5 →
D3Z7P3	—	0.935	D3Z7P3 →
GLS	Glutaminase kidney isoform, mitochondrial	0.932	landscape →
Q2HJ19	—	0.932	Q2HJ19 →
Q5RB35	—	0.932	Q5RB35 →
KCNT1	Potassium channel subfamily T member 1	0.932	landscape →
A0A2R8RWN9	—	0.931	A0A2R8RWN9 →
Q9GKY0	—	0.931	Q9GKY0 →
Q5SRY7	—	0.930	Q5SRY7 →
Q9UL63	—	0.930	Q9UL63 →
Q9UKB1	—	0.930	Q9UKB1 →
Q91854	—	0.929	Q91854 →
Q28D01	—	0.928	Q28D01 →
Q58D84	—	0.928	Q58D84 →
Q99PV3	—	0.928	Q99PV3 →
Q5R9Y1	—	0.928	Q5R9Y1 →
Q12841	—	0.927	Q12841 →
Q7RTP6	—	0.927	Q7RTP6 →
Q6ZPR4	—	0.927	Q6ZPR4 →
Q9Z258	—	0.927	Q9Z258 →
Q8VEG6	—	0.927	Q8VEG6 →